Thursday, February 26, 2026

In Detail Full day, Thursday, February 26, 2026, Timezone: America/Chicago

Cancer blood test fails to catch disease earlier in major study

medicalxpress - A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.

AI Summary: A large trial evaluating GRAIL’s multi‑cancer blood screening test failed to meet its primary goal of earlier cancer detection. The disappointing result casts doubt on the test’s clinical utility for population screening, sparks debate over marketing and clinical use, and prompts calls for clearer evidence before widespread adoption.

Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial

Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...

AI Summary: In a direct comparator study, Eli Lilly’s marketed obesity drug Zepbound produced greater mean weight loss than Novo Nordisk’s experimental CagriSema. The result complicates the competitive landscape for anti‑obesity medicines and will influence prescribers, payers and the almighty market share tussle.